An open label study of quetiapine in patients with schizophrenia and alcohol disorders

Mary F. Brunette, Ree Dawson, Christopher O'Keefe, Peter Buckley, Alan I. Green

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Preliminary studies suggest that quetiapine, a mixed dopaminergic and serotonergic agent used for the treatment of psychosis, may decrease substance use in patients with schizophrenia. Method: A three-month, uncontrolled, open-label prospective study of 23 outpatients with schizophrenia or schizoaffective disorder and co-occurring alcohol use disorder was conducted at two sites. Due to substantial site differences, outcomes are reported separately for each site on the 16 study subjects who completed at least one month of quetiapine treatment (mean dose 472 ± 255mg). Results: At Site 1 (n=11), mean days of drinking each week decreased, but not significantly (3.18 ± 1.63 to 2.71 ± 2.32, t=1.2, df=10, p=.26). At Site 2 (n=5), mean days of drinking dropped from 3.1 ± 1.19 to 0.24 ± 0.17 (t=5.0, df=4, p=0.007). At that site, patients were younger, had fewer prior hospitalizations, and the majority (83.3%) were recently in a psychiatric inpatient unit. Conclusion: Quetiapine may have a positive impact on alcohol use in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol use disorder. Randomized, controlled trials are needed to clarify whether quetiapine has a specific effect on alcohol use in patients with such co-occurring disorders.

Original languageEnglish (US)
Pages (from-to)203-211
Number of pages9
JournalMental Health and Substance Use: Dual Diagnosis
Volume2
Issue number3
DOIs
StatePublished - Oct 1 2009

Fingerprint

Schizophrenia
Alcohols
Psychotic Disorders
Drinking
Serotonin Agents
Dopamine Agents
Psychiatry
Inpatients
Hospitalization
Outpatients
Randomized Controlled Trials
Prospective Studies
Quetiapine Fumarate
Therapeutics

Keywords

  • Alcohol disorder
  • Quetiapine
  • Schizophrenia

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Psychiatry and Mental health

Cite this

An open label study of quetiapine in patients with schizophrenia and alcohol disorders. / Brunette, Mary F.; Dawson, Ree; O'Keefe, Christopher; Buckley, Peter; Green, Alan I.

In: Mental Health and Substance Use: Dual Diagnosis, Vol. 2, No. 3, 01.10.2009, p. 203-211.

Research output: Contribution to journalArticle

Brunette, Mary F. ; Dawson, Ree ; O'Keefe, Christopher ; Buckley, Peter ; Green, Alan I. / An open label study of quetiapine in patients with schizophrenia and alcohol disorders. In: Mental Health and Substance Use: Dual Diagnosis. 2009 ; Vol. 2, No. 3. pp. 203-211.
@article{ebae2b5c6fdb48ba91fcfb20f27c227c,
title = "An open label study of quetiapine in patients with schizophrenia and alcohol disorders",
abstract = "Background: Preliminary studies suggest that quetiapine, a mixed dopaminergic and serotonergic agent used for the treatment of psychosis, may decrease substance use in patients with schizophrenia. Method: A three-month, uncontrolled, open-label prospective study of 23 outpatients with schizophrenia or schizoaffective disorder and co-occurring alcohol use disorder was conducted at two sites. Due to substantial site differences, outcomes are reported separately for each site on the 16 study subjects who completed at least one month of quetiapine treatment (mean dose 472 ± 255mg). Results: At Site 1 (n=11), mean days of drinking each week decreased, but not significantly (3.18 ± 1.63 to 2.71 ± 2.32, t=1.2, df=10, p=.26). At Site 2 (n=5), mean days of drinking dropped from 3.1 ± 1.19 to 0.24 ± 0.17 (t=5.0, df=4, p=0.007). At that site, patients were younger, had fewer prior hospitalizations, and the majority (83.3{\%}) were recently in a psychiatric inpatient unit. Conclusion: Quetiapine may have a positive impact on alcohol use in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol use disorder. Randomized, controlled trials are needed to clarify whether quetiapine has a specific effect on alcohol use in patients with such co-occurring disorders.",
keywords = "Alcohol disorder, Quetiapine, Schizophrenia",
author = "Brunette, {Mary F.} and Ree Dawson and Christopher O'Keefe and Peter Buckley and Green, {Alan I.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1080/17523280903156073",
language = "English (US)",
volume = "2",
pages = "203--211",
journal = "Mental Health and Substance Use: Dual Diagnosis",
issn = "1752-3281",
publisher = "Routledge",
number = "3",

}

TY - JOUR

T1 - An open label study of quetiapine in patients with schizophrenia and alcohol disorders

AU - Brunette, Mary F.

AU - Dawson, Ree

AU - O'Keefe, Christopher

AU - Buckley, Peter

AU - Green, Alan I.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: Preliminary studies suggest that quetiapine, a mixed dopaminergic and serotonergic agent used for the treatment of psychosis, may decrease substance use in patients with schizophrenia. Method: A three-month, uncontrolled, open-label prospective study of 23 outpatients with schizophrenia or schizoaffective disorder and co-occurring alcohol use disorder was conducted at two sites. Due to substantial site differences, outcomes are reported separately for each site on the 16 study subjects who completed at least one month of quetiapine treatment (mean dose 472 ± 255mg). Results: At Site 1 (n=11), mean days of drinking each week decreased, but not significantly (3.18 ± 1.63 to 2.71 ± 2.32, t=1.2, df=10, p=.26). At Site 2 (n=5), mean days of drinking dropped from 3.1 ± 1.19 to 0.24 ± 0.17 (t=5.0, df=4, p=0.007). At that site, patients were younger, had fewer prior hospitalizations, and the majority (83.3%) were recently in a psychiatric inpatient unit. Conclusion: Quetiapine may have a positive impact on alcohol use in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol use disorder. Randomized, controlled trials are needed to clarify whether quetiapine has a specific effect on alcohol use in patients with such co-occurring disorders.

AB - Background: Preliminary studies suggest that quetiapine, a mixed dopaminergic and serotonergic agent used for the treatment of psychosis, may decrease substance use in patients with schizophrenia. Method: A three-month, uncontrolled, open-label prospective study of 23 outpatients with schizophrenia or schizoaffective disorder and co-occurring alcohol use disorder was conducted at two sites. Due to substantial site differences, outcomes are reported separately for each site on the 16 study subjects who completed at least one month of quetiapine treatment (mean dose 472 ± 255mg). Results: At Site 1 (n=11), mean days of drinking each week decreased, but not significantly (3.18 ± 1.63 to 2.71 ± 2.32, t=1.2, df=10, p=.26). At Site 2 (n=5), mean days of drinking dropped from 3.1 ± 1.19 to 0.24 ± 0.17 (t=5.0, df=4, p=0.007). At that site, patients were younger, had fewer prior hospitalizations, and the majority (83.3%) were recently in a psychiatric inpatient unit. Conclusion: Quetiapine may have a positive impact on alcohol use in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol use disorder. Randomized, controlled trials are needed to clarify whether quetiapine has a specific effect on alcohol use in patients with such co-occurring disorders.

KW - Alcohol disorder

KW - Quetiapine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=75149167156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149167156&partnerID=8YFLogxK

U2 - 10.1080/17523280903156073

DO - 10.1080/17523280903156073

M3 - Article

AN - SCOPUS:75149167156

VL - 2

SP - 203

EP - 211

JO - Mental Health and Substance Use: Dual Diagnosis

JF - Mental Health and Substance Use: Dual Diagnosis

SN - 1752-3281

IS - 3

ER -